Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase – Should You Buy?

Genmab A/S (NASDAQ:GMAB) shares saw unusually-high trading volume on Wednesday . Approximately 4,599,016 shares were traded during mid-day trading, an increase of 203% from the previous session’s volume of 1,518,271 shares.The stock last traded at $19.79 and had previously closed at $19.58.

Analysts Set New Price Targets

A number of brokerages have weighed in on GMAB. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Redburn Atlantic started coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Price Performance

The company has a fifty day moving average price of $21.07 and a 200 day moving average price of $23.82. The stock has a market cap of $13.11 billion, a P/E ratio of 19.24, a P/E/G ratio of 0.57 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same quarter last year, the firm posted $0.47 EPS. As a group, sell-side analysts expect that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares in the last quarter. Blue Trust Inc. raised its position in Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after buying an additional 3,880 shares during the last quarter. R Squared Ltd bought a new position in Genmab A/S during the 4th quarter valued at $93,000. Allspring Global Investments Holdings LLC boosted its holdings in Genmab A/S by 43.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock worth $113,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC bought a new stake in shares of Genmab A/S in the 3rd quarter worth $192,000. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.